Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Non-Current Deffered Revenue (2017 - 2018)

Rocket Pharmaceuticals (RCKT) has disclosed Non-Current Deffered Revenue for 2 consecutive years, with $457000.0 as the latest value for Q4 2018.

  • Quarterly Non-Current Deffered Revenue rose 327.1% to $457000.0 in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $457000.0 through Dec 2018, up 327.1% year-over-year, with the annual reading at $457000.0 for FY2018, 327.1% up from the prior year.
  • Non-Current Deffered Revenue hit $457000.0 in Q4 2018 for Rocket Pharmaceuticals, up from $438000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $598000.0 in Q1 2018 to a low of $107000.0 in Q4 2017.